Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma

BACKGROUND: Human urothelial carcinoma (UC) has a high tendency to recur and progress to life-threatening advanced diseases. Advanced therapeutic regimens are needed to control UC development and recurrence. METHODS: We pursued in vitro and in vivo studies to understand the ability of a triple combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pattarawat, Pawat, Hong, Tian, Wallace, Shelby, Hu, Yanchun, Donnell, Robert, Wang, Tzu-Hao, Tsai, Chia-Lung, Wang, Jinquan, Wang, Hwa-Chain Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374627/
https://www.ncbi.nlm.nih.gov/pubmed/32390005
http://dx.doi.org/10.1038/s41416-020-0877-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374627/
https://www.ncbi.nlm.nih.gov/pubmed/32390005
http://dx.doi.org/10.1038/s41416-020-0877-8

Ejemplares similares